NxStage Medical (NXTM) Raised to Sell at BidaskClub

NxStage Medical (NASDAQ:NXTM) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity reaffirmed a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of NxStage Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. ValuEngine cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Northland Securities reaffirmed a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating and nine have given a hold rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $30.25.

Shares of NxStage Medical (NASDAQ:NXTM) opened at $24.36 on Monday. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80. The firm has a market cap of $1,610.00, a PE ratio of -116.00 and a beta of -0.08.

In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $24.88, for a total transaction of $87,080.00. Following the completion of the transaction, the senior vice president now owns 13,770 shares of the company’s stock, valued at $342,597.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 10,500 shares of company stock valued at $265,860. Insiders own 4.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Cowen Inc. acquired a new position in NxStage Medical during the third quarter worth about $1,908,000. Gabelli Funds LLC acquired a new position in NxStage Medical during the third quarter worth about $4,941,000. JPMorgan Chase & Co. raised its stake in NxStage Medical by 239,738.6% during the third quarter. JPMorgan Chase & Co. now owns 1,870,741 shares of the medical device company’s stock worth $51,502,000 after acquiring an additional 1,869,961 shares in the last quarter. ARP Americas LLC acquired a new position in NxStage Medical during the third quarter worth about $11,219,000. Finally, Allianz Asset Management GmbH acquired a new position in NxStage Medical during the third quarter worth about $9,384,000. 85.56% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2018/02/07/nxstage-medical-nxtm-raised-to-sell-at-bidaskclub.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply